Home   Chapter Home   Jobs   Conferences   Fellowships   Books


Transfusion medicine

Tranfusion reaction

Transfusion related acute lung injury (TRALI)

Reviewer: Huy Phu Pham, M.D. (see Reviewers page)
Revised: 5 November 2011, last major update September 2011
Copyright: (c) 2007-2011, PathologyOutlines.com, Inc.


● Per FDA data from 2005–2009, TRALI is the leading cause of transfusion-related mortality, causing 48% of deaths (link)
● Incidence of TRALI is decreasing
● Both overdiagnosed and underdiagnosed
● Computer screening identifies more cases of post-transfusion hypoxemia than are reported voluntarily (Am J Clin Pathol 2005;124:601)
● Mostly a clinical diagnosis
● TRALI has been reported following transfusion of all blood products
● Estimated incidence between 0.014% to 0.08% per blood product transfused
● For pRBC, incidence estimated at 1 per 5000 units
● Occurs most commonly with products containing > 60 mL plasma

Criteria for TRALI diagnosis: (link)
1. TRALI criteria
       a. ALI (Acute lung injury)
       ● Acute onset
       ● Hypoxemia-research Setting: PaO2/FiO2< 300 or SPO2 90% on room air
       ● Nonresearch setting: PzO2/FiO2 < 300 or SPO2 < 90% on room air or other clinical evidence of hypoxemia
       ● Bilateral infiltrates on frontal CXR
       ● No evidence of left atrial hypertension (i.e., circulatory overload)
       b. No preexisting ALI before transfusion
       c. Symptoms occur during or within 6 hrs of transfusion
       d. No temporal relationship to an alternative risk factor for ALI
2. Possible TRALI
       a. Acute lung injury / ALI
       b. No preexisting ALI before transfusion
       c. Symptoms occur during or within 6 hrs of transfusion
       d. Clear temporal relationship to an alternative risk factor for ALI

Clinical manifestation

● Varies from mild to life threatening
● Sudden onset of respiratory distress within 6 hours of transfusion
● Fever, hypotension, tachycardia
● Physical exam should NOT show any sign of fluid overload


● Not fully understood

Immune mechanism
● Passive transfer of HLA or neutrophil antibodies from donor to blood product recipient --> leukoagglutination in the pulmonary vasculature --> complement activation --> alveolar damage --> increase in permeability of pulmonary circulation --> pulmonary edema (Hematology Am Soc Hematol Educ Program 2006;497, Am J Clin Pathol 1999;112:216)

Non-immune mechanism
● Transfusion of other elements, including biologically active lipids that accumulate during the storage --> alveolar damage --> increase in permeability of pulmonary circulation --> pulmonary edema
● Both immune and non-immune mechanisms likely work through a “two-hit” mechanism
● First hit: patient’s underlying condition primes the lung’s endothelium and leukocytes
● Second hit: transfusion of HLA or neutrophil antibodies or biologically active lipid --> pulmonary edema
● Granulocytes accumulate within pulmonary vasculature and extravasate into alveoli (Am J Clin Pathol 1999;112:216)


● Respiratory distress during or shortly after transfusion of blood products
● By definition, no findings of circulatory overload, no preexisting acute lung injury or ARDS
● CXR shows bilateral infiltrate without cardiomegaly – important in helping to make the diagnosis
● If intubation is required, then frothy pink secretions might be seen
● Need to distinguish TRALI from other cause of ARDS, such as transfusion-associated circulatory overload (TACO), bacterial contamination, allergic reaction, ARDS, pulmonary embolism, pulmonary hemorrhage
● TRALI does not respond to diuretics (TACO does)

No typical laboratory findings associated with TRALI:
● Leukopenia, neutropenia, and monocytopenia have been reported
● Testing for lymphocyte and granulocyte antibodies is not required for diagnosis and is not predictive (Vox Sang 2007;93:70, Vox Sang 2007;92:247)


● Stop the transfusion
● Report the transfusion to transfusion medicine division to start the investigation
● Supportive management only
● Mechanical ventilation may be needed in severe cases
● Most patients improve within 48–96 hours
● Mortality is 5–10%

TRALI investigation:
● Very important
● Patients with a history of TRALI should not receive any blood products from the implicated donors
● Hospital should notify blood center following a potential case of TRALI
● Investigate pregnancy, transfusion or transplantation history of the donor
● Determine if donor has anti-HLA or anti-neutrophil antibodies; if yes, then patient is also tested to see whether an antigen-antibody interaction could be implicated


● Defer donors confirmed to be implicated in TRALI
● In 2003, UK began to use only male plasma
● In 2006, the AABB recommended that hospitals and blood centers implement TRALI mitigation strategies, such as use of male-only plasma

Risk factors

● Allogeneic red blood cell transfusion is an independent risk factor for ARDS in the intensive care unit population; follows a dose-response relationship (Crit Care 2007;11:R63)
● Transfusions of plasma-rich blood products, FFP and platelets may have higher risk of ARDS than RBC transfusions (Chest 2007;131:1308)
● Restrictive transfusion policies reduce late onset ARDS in trauma patients (J Trauma 2007;63:1)
● Plasma from female donors (Transfusion 2007;47:599)

Underlying disease of the patients:
● Critically ill patients (Crit Care Med 2007;35:1645), sepsis, chronic alcohol abuse
● Possibly presence of donor antigranulocyte or HLA class II antibodies (Am J Respir Crit Care Med 2007;176:886), increasing number of units of whole blood transfused (Am J Clin Pathol 2007;128:128)

Case reports

● Transfusions between mother and daughter (Am J Clin Pathol 2004;121:590)
● 2 cases in children (Transfus Med 2006;16:343)
● 67 year old man with transfusion for iron deficiency anemia (CMAJ 2007;177:149), recurrence 2 years later (Transfus Med 2007;17:192)

End of Transfusion Medicine > Tranfusion reaction > Transfusion related acute lung injury (TRALI)

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at [email protected] with any questions (click here for other contact information).